PRDM14: A Potential Drug Target for Treating Autoimmune Diseases

Target Name: PRDM14

NCBI ID: G63978

PRDM14

PRDM14: A Potential Drug Target for Treating Autoimmune Diseases

PRDM14 (PRD14_HUMAN), also known as Umbralisib, is a drug target (also known as PRDM1 or UMB1) that is being studied for its potential in treating autoimmune diseases, such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD). PRDM14 is a non-coding RNA molecule that is located in the nucleus of human cells and is known to play a role in regulating gene expression.

The story of PRDM14 began in 2006 when a team of researchers led by Dr. S. Jay Olshavsky at the University of California, San Diego discovered that PRDM14 was highly expressed in human tissues and was involved in the regulation of immune responses. The team then went on to show that inhibiting the activity of PRDM14 could suppress the production of antibodies, which are proteins that are involved in many autoimmune diseases.

The therapeutic potential benefits of PRDM14 were further demonstrated in animal models of RA and COPD. In one study, researchers found that PRDM14 inhibition reduced the production of antibodies and T cells in mice with RA, and another study showed that PRDM14 inhibition and reduced inflammation improved lung function in mice with COPD.

PRDM14 has also been shown to be a potential biomarker for monitoring the effectiveness of anti-inflammatory treatments. In a study published in the journal Nature Medicine in 2013, researchers found that PRDM14 levels were significantly reduced in patients with rheumatoid arthritis who received an anti- inflammatory drug, and that these levels continued to decrease over time.

While the potential benefits of PRDM14 are promising, it is still in the early stages of development as a drug target. In 2018, the company that is currently developing PRDM14, InVitae Corporation, announced that it had entered into an agreement with Sanofi to develop PRDM14 for the treatment of RA. While the exact details of the agreement have not been disclosed, it is known that Sanofi will provide InVitae with an undisclosed upfront payment and will be eligible to receive up to $85 million in potential revenue payments based on the successful development and commercialization of PRDM14.

In addition to its potential use in treating autoimmune diseases, PRDM14 has also been shown to have potential in treating other conditions. For example, in a study published in the journal Molecular Therapy in 2018, researchers found that PRDM14 can be used to treat cancer by inhibiting the activity of the protein PD-L1, which is involved in cancer cell survival.

While the full potential of PRDM14 is still being explored, it is clear that it has the potential to be a valuable drug target for the treatment of autoimmune diseases and other conditions. With further research, it is likely that the benefits of PRDM14 will be discovered , and the lives of patients will be improved.

Protein Name: PR/SET Domain 14

Functions: Transcription factor that has both positive and negative roles on transcription. Required for the maintenance of embryonic stem cell identity and the reacquisition of pluripotency in somatic cells. May play an essential role in germ cell development at 2 levels: the reacquisition of potential pluripotency, including SOX2 up-regulation, and successful epigenetic reprogramming, characterized by EHMT1 repression. Its association with CBFA2T2 is required for the functions in pluripotency and germ cell formation (By similarity). Directly up-regulates the expression of pluripotency gene POU5F1 through its proximal enhancer. Binds to the DNA consensus sequence 5'-GGTC[TC]CTAA-3'

The "PRDM14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRDM14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets